This article was generated with the support of AI and reviewed by an editor. This development comes as a significant step, especially considering the current long-acting injectable  LAI  olanzapine carries an FDA black box warning for Post injection Delirium Sedation Syndrome  PDSS , which has limited its use. Teva is leading the development and will handle the global commercialization of this olanzapine LAI.
Teva is developing a new long-acting injectable olanzapine LAI that does not carry the FDA black box warning for Post injection Delirium Sedation Syndrome (PDSS), unlike the current LAI olanzapine. Teva will lead the development and global commercialization of this new LAI.